AI-Designed Obesity Drug ISM0676 Shows 31.3% Weight Loss in Preclinical Trials

February 16, 2026

In a breakthrough for the next generation of metabolic medicine, the generative AI-driven biotech firm Insilico Medicine has announced the nomination of ISM0676 as a preclinical candidate for the treatment of obesity. New data released in late January 2026 reveals that the oral drug, developed in record time using artificial intelligence, achieved up to 31.3% body weight loss in animal models when combined with existing therapies.

The discovery marks a significant milestone in the global effort to combat an obesity epidemic that now affects over one billion people worldwide. By targeting the glucose-dependent insulinotropic polypeptide receptor (GIPR), ISM0676 offers a potentially more effective, “muscle-sparing” alternative to current blockbuster injectables.

The Science: Beyond Appetite Suppression

Current “gold standard” obesity treatments, such as semaglutide (marketed as Ozempic and Wegovy), primarily target the GLP-1 receptor to suppress appetite and slow digestion. While effective, these drugs often lead to a “plateau” in weight loss and, concerningly, a loss of lean muscle mass alongside fat.

ISM0676 takes a different tactical approach. It is a GIPR antagonist, meaning it blocks a specific receptor involved in how the body stores fat and manages insulin. In the study involving diet-induced obese (DIO) mice:

• Monotherapy: ISM0676 alone reduced body weight by 10.4% over 27 days.

• Combination Therapy: When paired with semaglutide, the synergy resulted in a staggering 31.3% weight loss.

• Body Composition: Crucially, the treatment improved the lean mass-to-body weight ratio, suggesting that the weight lost was primarily fat, not vital muscle.

“The nomination of ISM0676 further enriches Insilico’s cardiometabolic pipeline driven by generative AI exploration,” said Dr. Feng Ren, Co-CEO and Chief Scientific Officer at Insilico Medicine. “We look forward to advancing this program… aiming to induce breakthroughs in chronic disease management.”

The AI Edge: 14 Months vs. 10 Years

Perhaps as significant as the drug’s efficacy is the speed of its creation. Traditional drug discovery typically spans five to ten years and requires the synthesis of thousands of chemical compounds. Insilico Medicine reached this preclinical milestone in just 14 months.

Using its Chemistry42 AI platform, the team synthesized fewer than 200 compounds before identifying ISM0676. The AI predicted not only the molecule’s ability to block the GIP receptor but also its safety, metabolic stability, and how it would interact with other drugs.

Dr. Alex Zhavoronkov, Founder and CEO of Insilico, noted that the company’s focus on metabolism is rooted in its link to aging. “Insilico has been investing into metabolic disease research with AI-driven speed and precision… bringing benefits for patients worldwide.”

Expert Perspectives and Human Translation

While the preclinical data is compelling, medical experts urge a measured “wait-and-see” approach. The transition from mouse models to human success—known as “translation”—is notoriously difficult in the obesity field.

“Preclinical synergies like this could enhance GLP-1 therapies by preserving muscle and sustaining loss,” says Dr. Priya Singh, an endocrinologist at Johns Hopkins who was not involved in the research. “However, human translation remains uncertain due to species differences in metabolism. Rodents often lose weight more rapidly and respond differently to GIPR modulation than humans do.”

Furthermore, critics of the “AI hype” point out that while AI can design molecules with incredible speed, it cannot bypass the rigorous, multi-year clinical trial process required by the FDA. Roughly 90% of drugs that show promise in preclinical stages ultimately fail in human trials due to unforeseen side effects or lack of efficacy.

Public Health: A Shift Toward Oral Combinations

If ISM0676 proves safe and effective in humans, the public health implications could be transformative. Currently, many patients struggle with the “rebound effect”—regaining up to two-thirds of lost weight within a year of stopping GLP-1 injections.

The promise of an oral small-molecule (a pill rather than an injection) that stabilizes metabolism could:

1. Increase Adherence: Patients are more likely to stick to a pill regimen than long-term weekly injections.

2. Protect Aging Populations: By preserving muscle mass, the drug could prevent the frailty often associated with rapid weight loss in older adults.

3. Lower Costs: AI-driven development can potentially reduce R&D costs by 50-70%, eventually making these life-saving medications more accessible to lower-income populations.

Looking Ahead

Insilico Medicine plans to move toward an Investigational New Drug (IND) filing, which would pave the way for human trials. If the current trajectory holds, Phase 1 clinical trials could begin as early as 2027-2028.

For now, the medical community maintains that while “next-gen” therapies are on the horizon, the foundation of obesity management remains lifestyle-based. Experts recommend that patients continue to prioritize balanced nutrition and the standard 150 minutes of moderate activity per week while following currently approved FDA treatments.

Key Stats at a Glance

References

• https://scitechdaily.com/ai-designed-obesity-drug-delivers-over-31-weight-loss-in-preclinical-tests/

Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.